About MedX Health

To develop and implement non-invasive, practical, drug-free and cost-effective skin analysis and assessment systems for use by trained medical professionals, as well as light therapeutics and imaging systems that can help to save lives and enhance patients’ quality of life and improve standards of care.

MedX Health Corp. is a medical device company that has been operating since 1999. Initially, the Company was focused on research, development, manufacturing and distribution of phototherapeutic medical devices, which use light energy in lower-level laser and LED. 
In 2011, the Company purchased the assets and business related to a technology called SIAscopy™, which is a medical device that is used to scan suspicious moles and lesions.

The SIAscopy technology utilizes light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey.

The Company’s original products, photobiomodulation (“PBM”) medical devices, use light energy in lower-level lasers and LEDs to provide effective treatment offering rapid, drug-free and non-invasive healing in the rehabilitation and dental markets, treating pain, tissue damage, swelling and inflammation. The Company has sold thousands of these products to clinical practitioners, academic facilities, hospitals, long-term care facilities, and to athletes and sports teams.

Executive Team


President and CEO

Scott has 28 years of leadership developing sustainable trusted relationships with key opinion leaders, strategic partners and industry influencers.


Before joining MedX in April, 2018, Scott was Vice President and General Manager of Laerdal Medical Canada with full P&L responsibility to open and build the organization in Canada. Annual revenues increased 16 fold under his tenure. Scott also has international experience, and served as VP of Sales in the New York office for 3.5 years, reorganizing and increasing the sales force by 60% and increasing revenues by 35%. He also opened and built the Latin American organization, growing the business 7 fold in 6 years.


Managing Director, Europe

Daniel’s specialty is high-tech commercialization strategy and implementation. Daniel is the former President and CEO of Environmental Waste International Inc. (a public company – TSX Venture: “EWS”) 


Prior to EWS, Daniel was CEO of Renewable Energy Management Inc. where his principal roles were to define strategy, streamline operations, and raise capital. He successfully raised $3.2 million in seed funding from strategic partners. Daniel studied engineering with a double diploma from École Centrale de Paris, France, and University of Stuttgart, Germany. He received his Ph.D. in materials engineering at Cambridge University, UK.


Chief Operating Officer

Louie has extensive operational healthcare experience. Louie is responsible for Clinical Affairs, Quality Control and Production.


Louie was Co-Clinical Director responsible for management, mergers and acquisitions for a group of several successful “G” Code and Schedule 5 OHIP physiotherapy and chiropractic clinics, introducing and utilizing laser therapy as a palliative modality. He was also a founder and held executive positions within several emerging growth Healthcare companies. Louie has a B. Sc. in Natural Health Sciences.


Chief Financial Officer

Jim has wide-reaching experience in senior financial executive roles in private and public companies in numerous sectors.


He has held CFO roles with several medical device and biopharmaceutical companies. Jim has for many years been part of a professional firm assisting companies ranging from emerging growth to entrepreneurial to large established companies, primarily with restructuring, growth initiatives and hands-on financial management. He is a Chartered Accountant and Certified Public Accountant.


Director of International Business Development

Larry is responsible for developing and managing an international network of MedX Product distributors for the MedX Siascopy Technology products (MoleMate) and the Therapeutic and Dental Laser Therapy Product line.


He also manages sales to some markets in the U.S. He has successfully developed and launched strategic sales and marketing plans for numerous medical devices, implementing them internationally, including Europe, Asia, Latin America, the Middle East and Australia. He is a graduate of the U.S. Naval Flight School, Pensacola, Florida, and served in combat in the United States Navy. He holds a BA in Marketing and Business from Iowa University.

Board of Directors

The MedX Board of Directors is composed of professionals who have experience in management, finance, manufacturing, research and development.

Robert von der Porten

Chairman and Director

Rob joined MedX in November, 2013 as Chief Executive Officer. He has an MBA from the Richard Ivey School of Business, and has nearly 40 years’ experience as an executive holding senior positions in a number of North American industrial, retail, manufacturing, marketing and technology companies.

Kenneth McKay


Mr. McKay is a Senior Partner in the intellectual property law firm Sim, Lowman, Ashton & McKay. Mr. McKay is an active litigator in the intellectual property bar in Canada and is the co-author of several books and papers relating to intellectual property and the marketing and licensing of technology.

N. Gary Van Nest


Mr. Van Nest is President of Sinalta Investments Ltd., Chairman of Woodland Biofuels Inc. and is a director of several other publicly traded companies. Mr. Van Nest has over 37 years of extensive experience in the brokerage, merchant banking, and investment management businesses.

David J. Hennigar


Mr. Hennigar is Chairman of the Board of Directors of Highliner Foods Inc., and the a Director of a number of publicly traded companies, with many years of experience in senior management positions.

Medical Advisory Board

Dr. Trevor Champagne

Dr. Champagne is Clinician in Quality and Innovation at Toronto’s Women’s College Hospital, and is a board certified dermatologist in Canada and the US.


Dr. Champagne has a Bachelor in Mathematics in Computer Science from the University of Waterloo and a B.Sc. in Molecular Biology and Biochemistry from Simon Fraser University. He received his MD degree from the University of Western Ontario and is a graduate of the University of Toronto Dermatology residency program. He is a Lecturer in the Division of Dermatology at the University of Toronto.

Dr. Daniel Siegel

Dr. Siegel is Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology, to its Medical Advisory Board.


Dr. Siegel received his medical degree from Albany Medical College in New York, and completed his residency in dermatology at Parkland Memorial Hospital in Dallas, Texas. He then pursued a fellowship in Mohs Micrographic Surgery and Dermatologic Surgery at Baylor College of Medicine in Houston, Texas. He also earned a Master of Science degree in management and policy from the W. Averell Harriman School for Management and Policy, State University of New York at Stony Brook, and holds an Advanced Certificate in Labor/Management.

Dr. Paul Cohen

Dr. Cohen is a board certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada. He is also a diplomat of the American Board of Dermatology and is a member of numerous associations, including the Canadian Dermatological Association and the Toronto Dermatological Society.


Dr. Cohen graduated from the University of Toronto Medical School in 1995, and completed his dermatology residence in 2001. He was awarded the Ben Fisher Galderma fellowship in clinical dermatology where he completed additional training in cosmetic, surgical and pediatric dermatology. Dr. Cohen provides regular dermatology-related commentary to a wide variety of media, including CTV, Global and CBC news outlets.

Dr. Joe Walls

Dr. Walls is a consultant plastic surgeon working at North West Anglia Hospitals Trust in Cambridgeshire, England and is a member of the British Association of Plastic, Reconstructive and Aesthetic Surgeons and The British Association of Aesthetic Surgeons.


Dr. Walls specializes in the diagnosis of skin cancer and surgical reconstruction. Dr. Walls regularly speaks internationally on the topic of skin cancer and has also been involved in and authored many research project publications.

Dr. Per Hall

Dr. Hall has been involved in image analysis for early detection of melanoma since the 1990s, initially as an Honorary Researcher in Computer Science at Birmingham University


where he supervised Bsc, MSC and PhD computer science projects. Having completed his training in Plastic and Reconstructive surgery he was appointed as an attending Consultant at the University Hospital in Cambridge UK (Addenbrookes Hospital NHS Foundation Trust). Much of this work has been published in scientific peer review journals or as bound Mastership theses. Dr. Hall helped write the first set of UK guidelines for the management of cutaneous melanoma.

Dr. Dennis Reich

Dr. Reich is a practicing physician with over 15 years’ experience as a general practitioner. He owns a Primacy Medical Center in Sudbury, has operated a number of medical clinics and has an extensive background in business and technology consulting.


Dr. Reich has a Biochemistry degree from Laurentian University and graduated with his medical degree from Queens University in 1996. He received a family practice degree from University of Ottawa in 2008. Dr. Reich is vice-president of the Sudbury and District Medical Society and has represented Sudbury on the Ontario Medical Association’s Council for many years.

News and Events

News and Events 2018
August 28, 2019MedX Health Corp. Announces Second Quarter 2019 Results
July 16, 2019New guidelines for head & neck cancer treatment opens light therapy market opportunities for MedX
May 17, 2019 Robert McWhirter on Marketcall discusses Medx (see min 45:10)
April 9, 2019MedX Health Signs Exclusive Distribution Agreement to Launch DermSecure in Brazil, where Skin Cancer is Prevalent
March 4, 2019MedX Health Corp. Announces Private Label Distributor Agreement for Selected Therapeutic
December 16, 2018Tormont 50 December Research on MedX Health Corp.
November 29, 2018MedX Health Corp. Announces Third Quarter 2018 Results
November 27, 2018MedX Signs MOU to Launch DermSecure in the Netherlands
November 27, 2018MedX Health Corp. Announces Private Placement Closing and a New $2.5 Million Private Placement
November 23, 2018MedX Health Corp. Announces Private Placement Closing and a New $2.5 Million Private Placement
November 14, 2018MedX Launches Strategic Artificial Intelligence Initiative
October 23, 2018 MedX Health Announces That Dr. Eggert Stockfleth Has Joined Its Medical Advisory Board
October 11, 2018Bob McWhirter discusses MedX Health
September 24, 2018MedX Announces Management Changes
September 10, 2018Tormont 50 September Research on MedX Health Corp.
September 04, 2018MedX Launches DermSecure™ Telemedicine Platform
August 23, 2018MedX Health Corp. Announces Second Quarter 2018 Results
August 16, 2018Interview with Scott Spearn, President Medx Health Corp.
April 16, 2018Tormont 50 April Research on MedX Health Corp.
April 04, 2018MedX Health Corp. - Announces Scott Spearn as President
March 03, 2018Tormont 50 Research on MedX Health Corp.
February 28, 2018MedX Health Corp. - Announces regulatory clearance for its SIAscopy medical devices in New Zealand
February 20, 2018MedX Health Corp. - Bob McWhirter on BNN spoke about MedX
February 13, 2018MedX Receives Corporate Citizenship Award from the Melanoma Network of Canada
January 30, 2018MedX Health Corp. - Announces SIAscopy order exceeding $100,000 for Spain
January 08, 2018MedX Health Corp. - 2018 Q&A with CEO Robert von der Porten
January 05, 2018Robert McWhirter, President of Selective Asset Management, calls MedX’s SIAscope technology “truly revolutionary” and investment in MedX shares presents a “great opportunity going forward” on BNN’s Market Call. VIDEO
News and Events 2017
November 29, 2017MedX Health Corp. announces launch of skin scanning service in the Netherlands
November 13, 2017Addition of Two Renowned International Skin Cancer Specialists to its Medical Scientific Advisory Board
November 09, 2017Avison Young Golf for A Cure & Global Day of Giving in honour of Sean Faught
October 30, 2017MedX Health Corp. and Blanc Labs complete design of cloud-based telemedicine platform to enable global deployment of MedX’s scanning devices across a broad network of centers
October 12, 2017MedX Health and Calian’s Primacy Management Join Together to Provide On-the-Spot Suspicious Mole and Lesion Scans at the Melanoma Network of Canada’s “Strides for Melanoma Walk for Awareness” Fundraiser
August 25, 2017Robert McWhirter, President of Selective Asset Management, interviewed on BNN, sees positive Q4 for MedX Health due to expansion of pilot projects with Calian Group and Air Canada, potential green light to sell in Mexico, strategic partnership with Melanoma Network of Canada, and potential sun destination property/travel partnerships.
May 25, 2017MedX and Melanoma Network of Canada announce strategic partnership
May 24,2017Joint Venture Marketing Partnership with OncoTech LLC
May 23, 2017Improved Revenues in First Quarter 2017 Results
May 03, 2017Dr. Paul Cohen, renowned board certified dermatologist, joins MedX Medical/Scientific Advisory Board
May 01, 2017May is Melanoma Awareness Month
Spring 2017Dermatology in Practice – What if we could cut skin cancer death rates in half?
April 26, 2017MedX signs a MOU with MP Médic in Quebec and expand MedX’s reach in Canada
April 20, 2017Introduction of SIAscopy skin imaging devices with a chain of Netherlands based health clinics
March 20, 2017FP Entrepreneur features MedX Health “Whack that mole”